| This week's sponsor is ICON. | |  | ICON Functional Solutions
Learn more about an economical delivery model that evolves with your needs with benefits beyond costs savings:
• improved strategic flexibility
• innovation
• ease of management
|
Featured Story | | | Saturday, June 3, 2017 Johnson & Johnson may soon be able to move prostate cancer med Zytiga into an earlier disease stage, thanks to game-changing new data that rolled out Saturday at ASCO. |
|
|
| This week's sponsor is Dohmen Life Science Services. | |  | |
Top Stories Sunday, June 4, 2017 Back in February, AstraZeneca announced that its Lynparza had become the first PARP inhibitor to find success outside of ovarian cancer, posting positive results among breast cancer patients. And Sunday, the British drugmaker revealed just how positive those results were. Monday, June 5, 2017 Analysts say the data back up the potential of using the two immuno-oncology drugs in combination, with improving response rates and good tolerability, at least in some cancers. Sunday, June 4, 2017 Chinese firm Nanjing Legend Biotech grabbed much attention at ASCO, showing that its CAR-T candidate could be a safe and effective way to treat relapsed or refractory multiple myeloma. Monday, June 5, 2017 Pfizer’s EGFR lung cancer candidate, dacomitinib, doesn’t have a pretty past. But the New York drugmaker has finally rung up a phase 3 victory. Sunday, June 4, 2017 Novartis’ Zykadia just won the right to challenge Pfizer’s Xalkori for the first-line ALK-positive lung-cancer crown. But the way Roche sees it, that crown is Alecensa’s for the taking, as soon as it can nab an FDA approval, too. Sunday, June 4, 2017 Since March, when Roche announced that adding Perjeta to blockbuster Herceptin staved off postsurgery breast cancer progression in early-stage patients, the question has been “By how much?” As it turns out, the answer is, “Not a lot.” Sunday, June 4, 2017 New data suggest immunotherapy could stall mesothelioma progression—and that when it comes to Bristol-Myers Squibb’s checkpoint inhibitors, two might be better than one. Friday, June 2, 2017 CHICAGO—When Merck & Co.’s Keytruda won approval last week to treat tumors based on a biomarker rather than location in the body, it was hailed as a big step for precision medicine. Hoping to be part of that journey, Loxo Oncology unveiled new larotrectinib data at ASCO Saturday. Sunday, June 4, 2017 Bayer and its stalwart Nexavar have had the first-line liver cancer field to themselves for years. But Eisai is doing its best to change that. Friday, June 2, 2017 Chasing biosim partners Mylan and Biocon for one of the top targets in the pharma industry, Celltrion reported Sunday that its version of Roche’s breast cancer med Herceptin stacked up to the reference blockbuster in a late-stage trial. | This week's sponsor is FierceBiotech. | |  | FierceBiotech Executive Breakfast at BIO | Tackling the Drug Price Problem: A Town Hall Debate
Drug pricing has taken over the public debate about the biopharma industry. What can drugmakers do to address the pricing outcry? Can new approaches to drug development and intensified data-gathering help prove that new products are worth their cost? Join us at BIO 2017 for this town hall style debate. |
| | | Philips inked two precision medicine deals concurrent with ASCO, a research deal with Memorial Sloan Kettering Cancer Center and a project with Illumina and Navican to widen access to precision medicine. FierceMedTech story IBM, which markets its Watson supercomputer to improve cancer treatment, unveiled three studies showing Watson agreed with doctors on a treatment course up to 96% of the time. FierceMedTech story Among all the many promos for oncology therapies at ASCO, only one campaign highlighted a class of drugs that hasn’t received FDA approval yet. FiercePharmaMarketing story | |
|
Resources Presented by: Alcami As the pharmaceutical industry races to meet the DSCSA November 2017 deadline, challenges and complexities of serialization are becoming clear. Join Alcami to discuss lessons learned, mistakes to avoid and gain insight on how to achieve compliance. Wednesday, May 17, 2017 | By Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Wednesday, May 3, 2017 | By Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored by: Halo Pharmaceuticals Agile. Flexible. Collaborative. Proven. That’s Halo Pharma – making contract clinical development and commercial manufacturing go smoothly. Presented by: Covance Discover how you can successfully mitigate risks and maximize trial success by creating a comprehensive strategy that plans for the difference in immunotherapy development and proactively monitors execution. Sponsored by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored by: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
